How Union Budget 2026–27 Accelerates Research-Led Pharmaceutical Growth — Insights by Mr Saransh

Presented on February 1, 2026, India’s Union Budget 2026–27 indicates a great change for the pharma industry. Mr Saransh Chaudhary, President – Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre, shared his insights on how the budget will reshape the healthcare sector.

According to Mr Chaudhary, the next phase of pharmaceutical growth will be built on knowledge, evidence, and scientific capability. The policy will strengthen research ecosystems and upgrade clinical and regulatory capacity, taking Indian pharma higher in the global chain.

Science-Backed Era

What this really means is that the upcoming time in the pharma sector will not be about manufacturing more medicines, but aiming for new infrastructure with better systems around quality, safety, and outcomes.

With programmes such as Biopharma SHAKTI, development of new education and research centres, new accredited clinical trial sites, a deeper emphasis on regulatory science, and strengthening domestic manufacturing capabilities, India is building a foundation of faster innovation and higher global trust.

Why This Matters?

India’s treatment expectations are changing with the disease profile, and the risk of misuse is more eminent than ever. These reforms are a welcome move, especially in segments like critical care and antimicrobial resistance (AMR). 

A deeper research ecosystem, stronger regulatory oversight, and clinical evidence are essential for advancing high-quality generics, complex therapies, and long-term treatment effectiveness.

What’s in it for the General Public?

The budget cuts import duty on select cancer and rare-disease medicines that can help bring prices down. This emphasis on affordability and patient access, along with innovation and evidence-building, will mature the healthcare economy.

For Venus Remedies, the budget supports our work and the fight against drug-resistant infections.